Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314857 | 0.94 | TLR8 (0.45) | TLR8TLR7DHFRADORA3ADORA2A | |
| SCHEMBL26792198 | 0.92 | TLR8 (0.43) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL26788083 | 0.92 | DHFR (0.35) | TLR8TLR7DHFRKDM1ASLC2A1 | |
| SCHEMBL23037545 | 0.89 | TLR7 (0.39) | TLR8TLR7DHFRFGFR1FGFR2 | |
| SCHEMBL30539906 | 0.89 | TLR7 (0.39) | TLR8TLR7DHFRFGFR1FGFR2 | |
| SCHEMBL23037577 | 0.87 | TLR8 (0.43) | TLR8TLR7DHFRADORA3ADORA2A | |
| SCHEMBL26782132 | 0.87 | TLR8 (0.36) | TLR8TLR7DHFRSLC2A1 | |
| SCHEMBL29314604 | 0.85 | TLR8 (0.43) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL23037637 | 0.85 | TLR8 (0.43) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL23037627 | 0.85 | TLR8 (0.47) | TLR8TLR7ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR8 210/4885TLR7 236/4885DHFR 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.